详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China [2]Chengdu University, Sichuan Industrial Institute of Antibiotics, Chengdu 610052, China [3]Analytical & Testing Center, Sichuan University, Chengdu 610064, China [4]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China

出处：

DOI：

ISSN：

摘要：

A series of novel polycyclic spiro-fused carbocyclicoxindoles were synthesized and investigated for their in vitro antiproliferative activities against nine human cancer cell lines. Five compounds (10i, 10l, 10n, 10p, and 10r) demonstrated anticancer activities against A2780s cells with IC50 values of less than 30 μM. In particular, compound 10i showed anticancer activities against seven cancer cell lines and stronger activities than cisplatin in A2780s, A2780T, CT26, and HCT116 cells. Further studies illustrated that compound 10i arrested cell cycle in G1 phase and induced apoptosis of HCT116 cells. This compound also effectively increased the protein levels of cleaved caspase-3, p53, and MDM2. Molecular docking results revealed that compound 10i could bind well to the p53-binding site on MDM2, indicating that it might work by blocking the MDM2-p53 interactions. Copyright © 2016 Elsevier Masson SAS. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区

化学

小类 | 1 区药物化学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药物化学

第一作者：

第一作者机构： [1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：